Abstract: The invention concerns a use of argon gas administered by inhalation in order to directly protect or preserve haemodynamics and to prevent cardiovascular failure by controlling the blood flow, blood pressure and blood diffusion throughout the body of a human patient suffering from cardiovascular disease requiring heart or vascular surgery, in particular an aneurysm of the aorta, a myocardial ischaemia, a severe heart failure or a cardiopathy requiring a surgical operation. The argon is preferably mixed with oxygen.

Abstract: Liquid ventilator and methods integrating the concept of total liquid ventilation (TLV) using liquid volumes below functional residual capacity (FRC) of mammal's lungs are disclosed. Beyond the automatization of the whole process, the technology has been up-scaled to confirm that TLV at residual volumes below FRC can provide a safe procedure while enabling the full potential of TLV in a mammal such as humans or adult-sized animals. Such tidal liquid ventilation strongly differs from the previously known TLV approach, opening promising perspectives for a safer clinical translation. Also disclosed are apparatus and method for safe and fast induction of hypothermia during liquid ventilation of a mammal.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.

Abstract: The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.

Abstract: Method for treatment of a body of a mammal in cardiac arrest, comprising the step of performing a therapeutic hypothermia of the body after the cardiac arrest has occurred, said therapeutic hypothermia comprising: cooling the body to a target temperature during a cooling time period, said cooling being performed by total liquid ventilation which comprises alternately filling lungs of the body with a cooling liquid and removing from the lungs said cooling liquid, maintaining the body at the target temperature for a hypothermia duration.

Abstract: The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.

Abstract: The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.

Abstract: Method for treatment of a body of a mammal in cardiac arrest, comprising the step of performing a therapeutic hypothermia of the body after the cardiac arrest has occurred, said therapeutic hypothermia comprising: cooling the body to a target temperature during a cooling time period, said cooling being performed by total liquid ventilation which comprises alternately filling lungs of the body with a cooling liquid and removing from the lungs said cooling liquid, maintaining the body at the target temperature for a hypothermia duration.